Intramuscular Glucagon

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 1Hypoglycemia

Phase 1

A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

CompletedNCT03339453

Eli Lilly and CompanyDiabetes Mellitus, Type 1, Hypoglycemia

Start: 2017-11-10End: 2018-01-13Updated: 2019-09-23

Phase 2

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

CompletedNCT01997411

Eli Lilly and CompanyDiabetes Mellitus, Type 1

Start: 2013-11-30End: 2015-01-31Updated: 2018-08-29

Phase 3

Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

CompletedNCT01994746

Eli Lilly and CompanyDiabetes Mellitus, Type 1

Start: 2013-11-30End: 2015-01-31Updated: 2019-09-23

Related Papers

Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials

Journal of the Endocrine Society2024-02-192 citations

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study

Diabetes Therapy2020-06-0831 citations